Skip to content

Effect of Atorvastatin and Amlodipine on pressure-diuresis curve

Effect of Atorvastatin and Amlodipine on pressure-diuresis curve - Effect of Atorvastatin and Amlodipine on pressure-diuresis curve

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006691
Enrollment
30
Registered
2011-11-08
Start date
2011-12-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with salt sensitive hypertension and LDL hyperlipemia

Interventions

A salt restricted diet for three days is given to the patient under 5 mg of amlodipine administration. Then 10mg of atorvastatin added, a salt restricted diet for three days is given to the patient.

Sponsors

Kyoto University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) hypertension (systoric BP>140mmHg or diastoric BP>90mmHg) 2) hyper LDL-C (>120mg/dl) without statin treatment 3) serum Cr < 3.0mg/dl 4) over 20 years old 5) obtain written informed consent.

Exclusion criteria

Exclusion criteria: 1) a patient who is treated with diuretics. 2) a patient who is treated with statins. 3) poor controlled hypertension (systoric BP>180mmHg or diastoric BP>110mmHg) 4) patient with heavy cardiovascular disease 5) hepatitis (ALT over three folds increase by normal limits) 6) pregnancy, child bearing potential pre- or nursing 7) uncontrolled arrhythmia 8) inadequate due to other reason by attending physician's judgments 9) history of hypersensitivity to atorvastatin

Design outcomes

Primary

MeasureTime frame
pressure-diuresis curve

Secondary

MeasureTime frame
changes in value of the following data from baseline to the end of examination(Blood Pressure, Urine volume, urinary sodium concentration, urinary potasium concentration, urinary neutrophil gelatinase associated lipocalin2 (NGAL) consentration, urinary 8OH-dG concentration, total cholesterol, low density lipoprotein, triglyceride, high density lipoprotein, high sensitive C-reactive protein, serum Urea, serum creatinine, serum Na,K,Cl, plasma renin activity, plasma aldosterone concentration )

Countries

Japan

Contacts

Public ContactMasato KASAHARA

Kyoto University Hospital Institute for Advancement of Clinical and Translational Science (iACT)

kasa@kuhp.kyoto-u.ac.jp075-751-4724

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026